Comparative Safety of Advanced Therapies in Patients With Ulcerative Colitis: An Administrative Claims-Based Study
In a real-world cohort of patients with UC, anti-ILs and JAK inhibitors were associated with a lower risk of serious infections and may offer net benefit, especially in patients with previous TNF antagonist exposure.
Authors
- Claudia Dziegielewski (ORCID: https://orcid.org/0000-0002-7309-1316)
- Shane W. Goodwin (ORCID: https://orcid.org/0009-0005-5820-078X)
- Namrata Singh (ORCID: https://orcid.org/0000-0001-7149-363X)
- Dhruv Ahuja
- Vipul Jairath (ORCID: https://orcid.org/0000-0002-1092-0033)
- Siddharth Singh (ORCID: https://orcid.org/0000-0002-2640-7269)
- Christopher Ma (ORCID: https://orcid.org/0000-0002-4698-9948)
- Kun‐Huei Yeh (ORCID: https://orcid.org/0000-0002-7306-174X)
- Ashwin N. Ananthakrishnan (ORCID: https://orcid.org/0000-0002-9436-1821)
- Ronghui Xu (ORCID: https://orcid.org/0000-0002-2822-0561)
- Sagar Patel
Institutions
- Western University (CA)
- Harvard University (US)
- University of Calgary (CA)
- University of Washington (US)
- London Health Sciences Centre (CA)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Mayo Clinic in Arizona (US)
- Human Longevity (United States) (US)
- Indira Gandhi Delhi Technical University for Women (IN)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.14309/ajg.0000000000003806
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00